Squarepoint’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $28.7M | Sell |
206,207
-37,079
| -15% | -$5.19M | 0.03% | 531 |
|
|
2025
Q4 | $29.9M | Sell |
243,286
-556,450
| -70% | -$67.6M | 0.03% | 579 |
|
|
2025
Q3 | $88.8M | Buy |
799,736
+459,202
| +135% | +$52.2M | 0.09% | 243 |
|
|
2025
Q2 | $37.8M | Buy |
340,534
+281,731
| +479% | +$30M | 0.04% | 487 |
|
|
2025
Q1 | $6.59M | Sell |
58,803
-9,179
| -14% | -$947K | 0.01% | 1265 |
|
|
2024
Q4 | $6.28M | Buy |
67,982
+34,462
| +103% | +$3.1M | 0.01% | 1464 |
|
|
2024
Q3 | $2.81M | Sell |
33,520
-1,840,916
| -98% | -$140M | ﹤0.01% | 1829 |
|
|
2024
Q2 | $129M | Buy |
1,874,436
+1,119,829
| +148% | +$74.7M | 0.21% | 69 |
|
|
2024
Q1 | $55.3M | Buy |
754,607
+664,099
| +734% | +$51.1M | 0.1% | 224 |
|
|
2023
Q4 | $7.33M | Buy |
90,508
+42,154
| +87% | +$3.28M | 0.01% | 1137 |
|
|
2023
Q3 | $3.62M | Sell |
48,354
-3
| -0% | -$231 | 0.01% | 1387 |
|
|
2023
Q2 | $3.73M | Buy |
+48,357
| New | +$3.86M | 0.01% | 1253 |
|
|
2023
Q1 | – | Sell |
-177,161
| Closed | -$14.7M | – | 3417 |
|
|
2022
Q4 | $15.2M | Buy |
177,161
+161,457
| +1,028% | +$12.8M | 0.06% | 345 |
|
|
2022
Q3 | $969K | Sell |
15,704
-212,100
| -93% | -$13.4M | ﹤0.01% | 1799 |
|
|
2022
Q2 | $14.1M | Sell |
227,804
-403,976
| -64% | -$25M | 0.08% | 287 |
|
|
2022
Q1 | $37.6M | Buy |
631,780
+351,325
| +125% | +$22.5M | 0.16% | 126 |
|
|
2021
Q4 | $20.4M | Buy |
280,455
+255,998
| +1,047% | +$17.6M | 0.05% | 302 |
|
|
2021
Q3 | $1.71M | Sell |
24,457
-76,315
| -76% | -$5.36M | ﹤0.01% | 1284 |
|
|
2021
Q2 | $6.94M | Buy |
100,772
+22,062
| +28% | +$1.47M | 0.03% | 597 |
|
|
2021
Q1 | $5.09M | Sell |
78,710
-796,719
| -91% | -$51.4M | 0.03% | 623 |
|
|
2020
Q4 | $51M | Buy |
875,429
+417,299
| +91% | +$25.2M | 0.38% | 33 |
|
|
2020
Q3 | $28.9M | Buy |
458,130
+441,687
| +2,686% | +$30.6M | 0.39% | 36 |
|
|
2020
Q2 | $1.26M | Buy |
+16,443
| New | +$1.26M | 0.02% | 819 |
|
|
2020
Q1 | – | Sell |
-683,459
| Closed | -$44.4M | – | 2107 |
|
|
2019
Q4 | $44.4M | Sell |
683,459
-276,315
| -29% | -$18M | 0.26% | 44 |
|
|
2019
Q3 | $60.8M | Buy |
959,774
+594,316
| +163% | +$38.9M | 0.54% | 20 |
|
|
2019
Q2 | $24.7M | Sell |
365,458
-247,995
| -40% | -$16.3M | 0.24% | 95 |
|
|
2019
Q1 | $39.9M | Buy |
613,453
+132,729
| +28% | +$8.82M | 0.42% | 38 |
|
|
2018
Q4 | $30.1M | Buy |
+480,724
| New | +$33.6M | 0.35% | 41 |
|
|
2018
Q3 | – | Sell |
-25,600
| Closed | -$1.81M | – | 2054 |
|
|
2018
Q2 | $1.81M | Sell |
25,600
-43,497
| -63% | -$3.07M | 0.02% | 674 |
|
|
2018
Q1 | $5.21M | Sell |
69,097
-33,494
| -33% | -$2.66M | 0.08% | 301 |
|
|
2017
Q4 | $7.35M | Buy |
+102,591
| New | +$7.79M | 0.13% | 176 |
|
|
2017
Q3 | – | Sell |
-46,700
| Closed | -$3.31M | – | 1707 |
|
|
2017
Q2 | $3.31M | Sell |
46,700
-68,300
| -59% | -$4.54M | 0.07% | 372 |
|
|
2017
Q1 | $7.81M | Sell |
115,000
-62,426
| -35% | -$4.39M | 0.22% | 109 |
|
|
2016
Q4 | $12.7M | Buy |
177,426
+80,809
| +84% | +$6.01M | 0.52% | 24 |
|
|
2016
Q3 | $7.64M | Buy |
+96,617
| New | +$7.85M | 0.51% | 30 |
|
|
2016
Q2 | – | Sell |
-48,179
| Closed | -$4.43M | – | 1201 |
|
|
2016
Q1 | $4.43M | Buy |
48,179
+30,269
| +169% | +$2.73M | 0.34% | 51 |
|
|
2015
Q4 | $1.81M | Buy |
+17,910
| New | +$1.86M | 0.2% | 104 |
|
|
2015
Q1 | – | Sell |
-13,500
| Closed | -$1.27M | – | 447 |
|
|
2014
Q4 | $1.27M | Buy |
+13,500
| New | +$1.4M | 1.23% | 14 |
|
Other funds holding GILD
VCM
VPM
Squarepoint's GILD Position: Q1 2026 in Review
Squarepoint reduced its Gilead Sciences (GILD) stake by 15% in Q1 2026, selling an estimated $5.19M and leaving 206,207 shares worth $28.7M. The position accounts for 0.03% of the portfolio, ranked #531.
Squarepoint first reported a position in GILD in Q4 2014 and has held it in 38 quarters since. The position peaked at $129M in Q2 2024. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Squarepoint held 206,207 shares of Gilead Sciences worth $28.7M as of Q1 2026.
- Squarepoint sold 37,079 Gilead Sciences shares in Q1 2026, an estimated $5.19M.
- Gilead Sciences made up 0.03% of Squarepoint's portfolio in Q1 2026, its #531 holding.
- Squarepoint first reported a position in Gilead Sciences in Q4 2014 and has held it in 38 quarters since.
- Squarepoint's Gilead Sciences position peaked at $129M in Q2 2024.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.